Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (351)	1/28/1999 10:30:00 AM
From: aknahow	Read Replies (1) \| Respond to of 712

Think details show slowing in rate of sales increase. Anyone that can please refute this. Not trying for a bullish spin. -- End sales to customers by Eli Lilly and Company [NYSE:LLY - news], Centocor's marketing "partner for ReoPro, were $108 million in the fourth quarter of 1998, a 35% increase from $80 million in the same period of 1997 and a 24% rise from $87 million in the third quarter of 1998. Centocor's sales to Lilly were $55.5 million for the 1998 fourth quarter, up 32.6% from the year-ago fourth quarter."